Healthcare >> CEO Interviews >> August 14, 2000
JOHN C. MARTIN, PhD has been President and CEO of Gilead Sciences, Inc.
since April 1996. He joined the company in October 1990 as Vice
President for Research and Development, was appointed Chief Operating
Officer in November 1995 and was appointed President and Chief Executive
Officer and elected to the Gilead Board of Directors in April 1996. From
1984 to 1990 he was employed at Bristol-Myers Squibb, where he was
Director of Antiviral Chemistry. Prior to Bristol-Myers Squibb, Dr.
Martin was employed at Syntex Corporation from 1978 to 1984. Dr. Martin
is the co-inventor of ganciclovir, a pharmaceutical now marketed by
Syntex for the treatment of cytomegalovirus infection. He is currently
President of the International Society for Antiviral Research. Dr.
Martin received his PhD in Organic Chemistry from the University of
Chicago. Profile
Dr. Martin: Gilead Sciences was founded 13 years ago to develop
therapies for viral diseases. I was the 35th employee,
